Ratings and dated fundamentals
Exact eligible report scores in ranking order. Ratings summarize dated reports, not future returns; report and market dates remain in the table. Showing the first 10 of 94 recorded values; the complete table remains available below.
See the complete ratings and dated fundamentals
Scroll sideways to compare all columns. Select a heading to sort.
| 1 | iRadimed Corporation | IRMD | 4 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $86.31 | $1,103,745,485.43 | 46.02 | 10.37 |
| 2 | Align Technology Inc | ALGN | 3.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $166 | $11,700,850,798 | 23.79 | 2.72 |
| 3 | Becton, Dickinson and Co. | BDX | 3.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $211.88 | $57,713,315,184 | 61.33 | Not reported |
| 4 | Boston Scientific Corp. | BSX | 3.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $42.75 | $61,964,980,240.5 | 17.73 | Not reported |
| 5 | CONMED Corporation | CNMD | 3.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $51.5 | $1,534,871,134.5 | 20.9 | 1.45 |
| 6 | Electromed, Inc. | ELMD | 3.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $27.17 | $227,308,648.71 | 20.11 | 4.21 |
| 7 | Edwards Lifesciences Corp | EW | 3.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $102.14 | $58,730,500,000 | 57.51 | 5.36 |
| 8 | GLOBUS MEDICAL INC | GMED | 3.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $71.05 | $9,539,308,989.7 | 17.11 | 1.99 |
| 9 | Haemonetics Corporation | HAE | 3.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $119.93 | $5,461,313,694.23 | 52.56 | Not reported |
| 10 | InMode Ltd. Ordinary Shares | INMD | 3.5 | 2025-12-31 | 2025 FY | openrouter::anthropic/claude-haiku-5.5 | 2026-11-06 | $13.33 | $767,063,812.76 | 8.17 | 1.12 |
| 11 | LivaNova PLC Ordinary Shares | LIVN | 3.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $89.99 | $4,957,261,941.91 | 25.28 | 3.61 |
| 12 | Medtronic plc | MDT | 3.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $101.8 | $130,216,237,202 | 24.89 | 2.56 |
| 13 | Merit Medical Systems Inc | MMSI | 3.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $87.23 | $5,226,389,288.12 | 32.64 | 3 |
| 14 | Insulet Corporation | PODD | 3.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $146.51 | $10,163,551,509.93 | 23.7 | 6.44 |
| 15 | Tactile Systems Technology, Inc. | TCMD | 3.5 | 2025-12-31 | 2025 FY | openrouter::anthropic/claude-haiku-5.5 | 2026-11-06 | $26.03 | $583,107,739.19 | 24.48 | 2.57 |
| 16 | Inspire Medical Systems, Inc. | INSP | 3 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $63.98 | $1,853,252,293.62 | 18.4 | 2.24 |
| 17 | Pro-Dex Inc New | PDEX | 3 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $63.16 | $202,096,063.16 | 16.8 | 4.1 |
| 18 | Penumbra, Inc. | PEN | 3 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $319.21 | $12,581,465,835.85 | 80.13 | 7.95 |
| 19 | Smith & Nephew plc | SNN | 3 | 2025-12-31 | 2025 FY | openrouter::anthropic/claude-haiku-5.5 | 2026-11-06 | $31.15 | $13,670,564,460.88 | 21.87 | 2.58 |
| 20 | TransMedics Group, Inc. Common Stock | TMDX | 3 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $88.24 | $3,064,917,835.92 | 21.22 | 5.57 |
| 21 | Viemed Healthcare, Inc. Common Shares | VMD | 3 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $9.13 | $345,963,948.22 | 22.14 | 2.28 |
| 22 | AtriCure, Inc. | ATRC | 2.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $58.54 | $2,980,990,446.82 | 200.29 | 5.59 |
| 23 | Baird Medical Investment Holdings Ltd Ordinary Share | BDMD | 2.5 | 2025-12-31 | 2025 FY | openrouter::anthropic/claude-haiku-5.5 | 2026-11-06 | $0.09 | $2,825,894.72 | Not reported | 0.09 |
| 24 | Bio-Rad Laboratories, Inc.Class A | BIO | 2.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $381.57 | $10,202,485,434.75 | 9.97 | 1.34 |
| 25 | Bioventus Inc. Class A Common Stock | BVS | 2.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $10.61 | $892,214,846.8 | 15.57 | 3.06 |
| 26 | Integra LifeSciences Holdings | IART | 2.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $13.42 | $1,044,089,097.92 | 80.23 | 0.98 |
| 27 | ICU Medical Inc | ICUI | 2.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $172.11 | $4,304,488,138.89 | 71.35 | Not reported |
| 28 | iRhythm Holdings, Inc. Common Stock | IRTC | 2.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $90.22 | $3,033,029,132.12 | Not reported | 17.13 |
| 29 | Anbio Biotechnology Class A Ordinary Shares | NNNN | 2.5 | 2025-12-31 | 2025 FY | openrouter::anthropic/claude-haiku-5.5 | 2026-11-06 | $3.89 | $170,736,768 | 26.66 | 5.66 |
| 30 | Neuropace, Inc. Common Stock | NPCE | 2.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $12.5 | $429,053,425 | Not reported | 36.11 |
| 31 | Envista Holdings Corporation Common stock, $0.01 par value per share | NVST | 2.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $25.17 | $4,035,882,089.46 | 6.37 | Not reported |
| 32 | RxSight, Inc. Common Stock | RXST | 2.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $4.54 | $190,358,667.88 | Not reported | 0.75 |
| 33 | SI-BONE, Inc. Common Stock | SIBN | 2.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $24.24 | $1,093,541,228.88 | Not reported | 5.92 |
| 34 | SANUWAVE Health, Inc. Common Stock | SNWV | 2.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $2.19 | $18,839,056.71 | 1.32 | 6.76 |
| 35 | Sensus Healthcare, Inc | SRTS | 2.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $2.86 | $47,081,488.74 | Not reported | 1.28 |
| 36 | Teleflex Incorporated | TFX | 2.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $150.87 | $5,983,694,447.07 | 19.64 | 1.71 |
| 37 | Xtant Medical Holdings, Inc. | XTNT | 2.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $0.29 | $40,599,335.62 | Not reported | 1.01 |
| 38 | AngioDynamics, Inc. | ANGO | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $11.73 | $493,298,698.5 | Not reported | 3.01 |
| 39 | Apyx Medical Corporation Common Stock | APYX | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $2.93 | $123,423,387.39 | Not reported | 12.3 |
| 40 | Alphatec Holdings, Inc. | ATEC | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $7.44 | $1,154,240,290.56 | Not reported | Not reported |
| 41 | Baxter International Inc. | BAX | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $25.79 | $13,342,409,768.52 | Not reported | 2.06 |
| 42 | CeriBell, Inc. Common Stock | CBLL | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $26.59 | $1,032,622,915.9 | Not reported | 8.79 |
| 43 | Cerus Corp | CERS | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $2.02 | $407,947,451.68 | Not reported | 5.34 |
| 44 | CVRx, Inc. Common Stock | CVRX | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $0.87 | $24,744,936.01 | Not reported | 1.79 |
| 45 | Enovis Corporation | ENOV | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $27.16 | $1,566,990,930.96 | Not reported | 1.05 |
| 46 | Inogen Inc | INGN | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $6.03 | $160,026,172.11 | Not reported | 0.92 |
| 47 | OrthoPediatrics Corp. Common Stock | KIDS | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $31.76 | $829,268,717.76 | Not reported | 2.44 |
| 48 | Pulmonx Corporation Common Stock | LUNG | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $2.56 | $111,489,702.4 | Not reported | 3.26 |
| 49 | Spectral AI, Inc. Class A Common Stock | MDAI | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $1.49 | $47,955,542.72 | Not reported | Not reported |
| 50 | Myomo Inc. | MYO | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $1.21 | $47,925,503.34 | Not reported | 8.22 |
| 51 | InspireMD, Inc. | NSPR | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $0.7 | $32,356,426.13 | Not reported | 1.03 |
| 52 | Orthofix Medical Inc. Common Stock (DE) | OFIX | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $7.87 | $320,565,624.96 | Not reported | 0.75 |
| 53 | Pulse Biosciences, Inc Common Stock (DE) | PLSE | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $53.29 | $3,919,422,159.96 | Not reported | 21.35 |
| 54 | QuidelOrtho Corporation Common Stock | QDEL | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $10.7 | $734,154,691.6 | Not reported | 0.41 |
| 55 | Sight Sciences, Inc. Common Stock | SGHT | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $10.08 | $560,236,088.16 | Not reported | 11.4 |
| 56 | Sanara MedTech Inc. Common Stock | SMTI | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $31.55 | $289,882,504.25 | Not reported | 36.53 |
| 57 | Neuronetics, Inc. Common Stock | STIM | 2 | 2025-12-31 | 2025 FY | openrouter::anthropic/claude-haiku-5.5 | 2026-11-06 | $2.15 | $167,115,868.65 | Not reported | 7.46 |
| 58 | TELA Bio, Inc. Common Stock | TELA | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $0.82 | $36,813,700.74 | Not reported | Not reported |
| 59 | Tandem Diabetes Care, Inc. | TNDM | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $16.91 | $1,180,213,935.86 | Not reported | 8.74 |
| 60 | Exagen Inc. Common Stock | XGN | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $5.81 | $140,749,219.59 | Not reported | 11.52 |
| 61 | DENTSPLY SIRONA Inc. | XRAY | 2 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $9.46 | $1,874,533,793.88 | Not reported | 1.38 |
| 62 | Autonomix Medical, Inc. Common Stock | AMIX | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $1.52 | $1,475,985.36 | Not reported | 0.47 |
| 63 | Heartbeam, Inc. Common Stock | BEAT | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $0.4 | $22,652,366.74 | Not reported | 2.77 |
| 64 | Bluejay Diagnostics, Inc. Common Stock | BJDX | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $2.35 | $1,165,414.35 | Not reported | 0.12 |
| 65 | BIOMERICA INC | BMRA | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $1.61 | $7,404,338.48 | Not reported | 2.03 |
| 66 | ClearPoint Neuro, Inc. Common Stock | CLPT | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $8.6 | $275,666,704.8 | Not reported | 10.11 |
| 67 | Cytosorbents Corp. | CTSO | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $4.8 | $15,082,257.6 | Not reported | Not reported |
| 68 | Femasys Inc. Common Stock | FEMY | 1.5 | 2025-12-31 | 2025 FY | openrouter::anthropic/claude-haiku-5.5 | 2026-11-06 | $1.37 | $4,142,834.79 | Not reported | 1.03 |
| 69 | Vyome Holdings, Inc. Common Stock | HIND | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $1.58 | $11,089,274.24 | Not reported | 1.52 |
| 70 | Hyperfine, Inc. Class A Common Stock | HYPR | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $0.72 | $76,302,017.35 | Not reported | 2.08 |
| 71 | IceCure Medical Ltd. Ordinary Shares | ICCM | 1.5 | 2025-12-31 | 2025 FY | openrouter::anthropic/claude-haiku-5.5 | 2026-11-06 | $0.68 | $3,157,345.95 | Not reported | 0.35 |
| 72 | Intelligent Bio Solutions Inc. Common Stock | INBS | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $1.97 | $5,964,115.9 | Not reported | 1.13 |
| 73 | Iridex Corp | IRIX | 1.5 | 2025-12-31 | 2025 FY | openrouter::anthropic/claude-haiku-5.5 | 2026-11-06 | $0.66 | $11,547,173.15 | Not reported | 3.17 |
| 74 | Milestone Scientific, Inc. Common Stock | MLSS | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $0.3 | $26,799,233.87 | Not reported | 7.72 |
| 75 | NeuroOne Medical Technologies Corporation Common Stock | NMTC | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $0.88 | $8,003,965.68 | Not reported | 2.12 |
| 76 | Neuraxis, Inc. | NRXS | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $6.24 | $78,360,453.6 | Not reported | 11.63 |
| 77 | Nuwellis, Inc. Common Stock | NUWE | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $4.58 | $292,332.24 | Not reported | Not reported |
| 78 | enVVeno Medical Corporation Common Stock | NVNO | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $6.73 | $4,676,178.98 | Not reported | 0.28 |
| 79 | Nexalin Technology, Inc. Common Stock | NXL | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $1.47 | $1,079,784.09 | Not reported | 0.71 |
| 80 | Nyxoah SA Ordinary Shares | NYXH | 1.5 | 2025-12-31 | 2025 FY | openrouter::anthropic/claude-haiku-5.5 | 2026-11-06 | $0.85 | $86,116,087.5 | Not reported | 1.49 |
| 81 | Orchestra BioMed Holdings, Inc. Ordinary Shares | OBIO | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $5.68 | $341,396,678.32 | Not reported | 11.6 |
| 82 | Outset Medical, Inc. Common Stock | OM | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $4.23 | $79,831,085.31 | Not reported | 0.96 |
| 83 | Polyrizon Ltd. Ordinary Shares | PLRZ | 1.5 | 2025-12-31 | 2025 FY | openrouter::anthropic/claude-haiku-5.5 | 2026-11-06 | $11.05 | $26,823,931.18 | Not reported | Not reported |
| 84 | Avita Medical, Inc. Common Stock | RCEL | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $16.59 | $518,730,571.45 | Not reported | Not reported |
| 85 | Senseonics Holdings, Inc. Common Stock | SENS | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $8.59 | $454,188,115.27 | Not reported | 5.03 |
| 86 | Sera Prognostics, Inc. Class A Common Stock | SERA | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $2.19 | $86,394,330.54 | Not reported | 1.65 |
| 87 | Treace Medical Concepts, Inc. Common Stock | TMCI | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $4.03 | $264,205,175.91 | Not reported | 4.29 |
| 88 | Tenon Medical, Inc. Common Stock | TNON | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $1.64 | $15,494.72 | Not reported | Not reported |
| 89 | Virax Biolabs Group Limited Ordinary Shares | VRAX | 1.5 | 2025-12-31 | 2025 FY | openrouter::anthropic/claude-haiku-5.5 | 2026-11-06 | $0.79 | $1,065,096 | Not reported | 0.15 |
| 90 | Vivos Therapeutics, Inc. Common Stock | VVOS | 1.5 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $0.09 | $1,885,058.76 | Not reported | Not reported |
| 91 | Adagio Medical Holdings, Inc Common Stock | ADGM | 1 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $0.06 | $1,441,458.79 | Not reported | Not reported |
| 92 | Envoy Medical, Inc. Class A Common Stock | COCH | 1 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $7.15 | $55,373,089.2 | Not reported | Not reported |
| 93 | Solana Company Class A Common Stock (DE) | HSDT | 1 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $1.93 | $116,685,296.79 | Not reported | 0.69 |
| 94 | ENDRA Life Sciences Inc. Common Stock | NDRA | 1 | 2025-12-31 | 2025 FY | anthropic/claude-haiku-5-5 | 2026-11-06 | $4.73 | $7,094,233.74 | Not reported | 1.12 |
No matching rows. Clear the filter to see all records.
94 companies with eligible ratings and dated fundamentals, from 95 eligible companies in this selection.
Inspect a rated peer
Ratings and dated fundamentals
Streamex Corp. Common Stock (STEX): source evidence dated 2026-11-07T12:42:51.530Z.
- Rank
- 1
- Company
- iRadimed Corporation
- Ticker
- IRMD
- Rating / 5
- 4
- Report date
- 2025-12-31
- Fiscal period
- 2025 FY
- Model
- anthropic/claude-haiku-5-5
- Market day
- 2026-11-06
The selected ticker, rating, report date and producing model match the first displayed row. Equal ratings use ticker order.
Which recorded peer has the highest usable rating?
The provider's peer set defines membership. It does not establish identical risk or business models. Read report dates and producing models.
NexusTrade stock ratings and report filters- Median market capitalization
- $269,935,940.36 · 94 / 94 displayed companies
- Median positive P/E (TTM)
- 22.92 · 30 / 94 displayed companies
- Median positive price / book
- 2.56 · 78 / 94 displayed companies
- Largest company by market cap
- Medtronic plc (MDT) · $130,216,237,202
- Largest company's share of displayed market cap
- 28.48% · Sum of displayed market caps; not portfolio weights or revenue exposure
Check each median’s included count and each company’s market date. These are unweighted summaries of displayed companies, not a sector index or revenue exposure.
Research STEX
Open a peer's company view and compare how it actually earns revenue with the anchor company.
Research STEXKeep reporting dates and units beside the answer, and inspect its original citations.
How these companies are related
Peer membership comes from the same related-company provider used by NexusTrade's stock research. The provider identifies related companies using news coverage and returns data. A related company can be a competitor or a thematic peer; this list does not imply identical products or financial exposure.
Peer membership was fetched 2026-10-12.
The rating determines the order after peer membership is selected. The anchor company is excluded. Companies without an eligible report rating or dated fundamentals are counted in coverage and left out of the ranked table.
What best means in this list
This list was refreshed on 2026-11-07 using existing company reports. The report date in each row is the date of the underlying analysis; refreshing the list does not create a new company report.
Best means the highest stored NexusTrade report ratings within this selection. Ratings use the product's 1-to-5 scale. The list sorts by rating from high to low, with ticker order breaking equal-rating ties. A rating summarizes a report; it does not predict a stock's return.
The peer set comes from the recorded related-company provider. Similarity defines which companies enter this comparison; it does not establish that they have equal business models, risk or expected returns.
What the leading companies do
The first 5 companies below lead the ratings in this snapshot; equal ratings are ordered by ticker. Their company profiles describe different businesses even when they share the Streamex Corp. Common Stock (STEX) selection.
These are company descriptions, not estimates of revenue from this theme. Industry membership does not identify a pure-play business or establish how much sales depend on it. Open the company profile and examine segment disclosures before treating an overlapping classification as equivalent exposure.
iRadimed Corporation (IRMD): 4 / 5
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. The company offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device. It also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. The company serves hospitals, acute care facilities, and outpatient imaging centers. It sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors. The company was incorporated in 1992 and is headquartered in Winter Springs, Florida.
Align Technology Inc (ALGN): 3.5 / 5
Align Technology, Inc. provides Invisalign clear aligners, Vivera retainers, and iTero intraoral scanners and services in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers Invisalign comprehensive package to treat adults and teens malocclusion and features, and orthodontic needs of teenage or younger patients; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients between the ages of six and ten years with a mixture of primary/baby and permanent teeth. This segment also provides Invisalign express, Invisalign lite, and Invisalign moderate; Invisalign Go, Invisalign Go express, and Invisalign Go Plus; retention products, Invisalign training, adjusting tools used by dental professionals during treatment, ancillary Invisalign accessory products, and other oral health products; Invisalign Professional Whitening system; Invisalign Palatal Expander, a 3D printed orthodontic device; and 3D printing solutions. Its Imaging Systems and CAD/CAM Services segment offers iTero intraoral scanning system, a single hardware platform for restorative or orthodontic procedures; exocad, a computer-aided design and computer-aided manufacturing software; orthodontist software for digital records storage, orthodontic diagnosis, and fabrication of printed models and retainers; and restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons. This segment also offers Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; Align Oral Health Suite, a digital interface for dental consultations; iTero TimeLapse technology for doctors or practitioners to compare a patient's historic 3D scans to the present-day scan; and subscription software, disposables, rents scanners, and pay per scan services. The company was incorporated in 1997 and is headquartered in Tempe, Arizona.
Becton, Dickinson and Co. (BDX): 3.5 / 5
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation systems, and medication inventory optimization and tracking systems; hemodynamic monitoring systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Boston Scientific Corp. (BSX): 3.5 / 5
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, proprietary programming software, radiofrequency ablation, indirect decompression systems, and intraosseous nerve ablation and deep brain stimulation systems. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat, and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
CONMED Corporation (CNMD): 3.5 / 5
CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures in the United States and internationally. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. It markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also provides battery-powered and autoclavable bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under Hall surgical brand name. In addition, the company offers general surgery products, including clinical insufflation systems under AirSeal brand; smoke removal devices under Buffalo Filter brand; endomechanical products, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors used in minimally invasive surgeries; and electrosurgical solution comprising monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems and other accessories. Further, the company provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products for the treatment of diseases of the dilatation, hemostasis, biliary, structure management, and infection prevention; and patient monitoring, including ECG and EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. The company was incorporated in 1970 and is headquartered in Largo, Florida.
Valuation and company size within this selection
These summaries use the 94 displayed companies. Each company retains its own market observation date in the ratings table above. Medians are unweighted; they are not a sector index valuation.
Positive P/E and price-to-book values are summarized separately. Missing, zero and negative values are excluded from those medians, with the included count shown. A lower multiple alone does not establish better value: profitability, growth, debt and business mix can differ.
Show the table · 5 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Median market capitalization | $269,935,940.36 | 94 / 94 displayed companies |
| Median positive P/E (TTM) | 22.92 | 30 / 94 displayed companies |
| Median positive price / book | 2.56 | 78 / 94 displayed companies |
| Largest company by market cap | Medtronic plc (MDT) | $130,216,237,202 |
| Largest company's share of displayed market cap | 28.48% | Sum of displayed market caps; not portfolio weights or revenue exposure |
No matching rows. Clear the filter to see all records.
Other business classifications in the list
A company can appear in several product and revenue classifications. These overlapping memberships help identify different business mixes to investigate; they are not verified revenue shares or mutually exclusive subindustries.
Show the table · 5 rows, 2 columns
| Additional classification | Matching displayed companies |
|---|---|
| Healthcare | 94 / 94 |
| Medical Devices | 94 / 94 |
| Technology | 82 / 94 |
| Hardware | 78 / 94 |
| Manufacturing | 62 / 94 |
No matching rows. Clear the filter to see all records.
Dates and coverage
Report dates range from 2025-12-31 to 2025-12-31. Market observations range from 2026-11-06 to 2026-11-06. These dates may differ across companies. Daily closes are not synchronized live quotes.
The selection includes 0 companies without a report, 0 with invalid latest rating metadata, 0 with older reports, 1 with missing required fundamentals and 0 with out-of-date market observations. Missing companies receive no substitute score.
How the ranking is built
The ranking uses the latest stored report at or before the refresh cutoff for each active eligible company. The report date, fiscal year/period and producing model remain visible. The latest invalid score is excluded; an older favorable score does not replace it. Publication policy stock-ratings-v1 accepts report ages up to 550 days and market observations up to 10 calendar days, with a positive close and market capitalization. Optional missing ratios remain not reported.
Report ages can differ substantially, particularly between annual and quarterly reports. Different producing models may also use different judgments. Read the date, fiscal period and model before comparing scores. Private report analysis and account data are not published here.
A refresh reads existing reports and market data. It does not rerun a model or create a new analysis. Compare business fundamentals and your own research constraints alongside the score before making a decision.